Please provide your email address to receive an email when new articles are posted on . Patients that were white, Black, Asian or “other” achieved similar efficacy results with Skyrizi. Similar ...
In an increasingly crowded psoriasis market, a raft of next-gen biologics is looking to topple an older suite of drugs for sales supremacy. Dermatologists seem to be on board with that shift, a good ...
Skyrizi ® (risankizumab-rzaa) is now available as a single-dose 150mg prefilled pen or syringe for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic ...
The Japanese Ministry of Health, Labour and Welfare (MHLW) approved SKYRIZI to treat patients with psoriasis based on highly positive results from several phase 2 and phase 3 studies. This includes ...
After Rinvoq won two new indications in as many months, AbbVie's immunology compatriot Skyrizi is getting in on the approval action. Skyrizi clinched a second nod, this time to treat adults with ...
MONTREAL, April 18, 2019 /CNW/ - AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, announced today that Health Canada has approved SKYRIZI™ (risankizumab) for the ...
- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe NORTH CHICAGO, Ill., Aug. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ...
NORTH CHICAGO, Ill., Sept. 12, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced top-line results from the Phase 3 SEQUENCE clinical trial evaluating risankizumab (SKYRIZI ®, 600 mg intravenous ...
AbbVie ABBV announced that the phase III maintenance study — FORTIFY — evaluating its psoriasis drug, Skyrizi (risankizumab) as maintenance treatment in patients with moderate-to- severe Crohn’s ...
April 23 (Reuters) - AbbVie Inc said on Tuesday that the U.S. Food and Drug Administration approved its Skyrizi drug as a treatment for plaque psoriasis at a time when its blockbuster psoriasis drug, ...
AbbVie (ABBV-0.69%) and Boehringer Ingelheim's Skyrizi performed better than Novartis' (NVS-0.32%) Cosentyx in a head-to-head late stage clinical trial in patients with the plaque psoriasis, an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results